Innovative NeuroTechnologies, Inc. (INT) is a development-stage biotechnology company operating in a “virtual mode” that is pursuing novel biologically-based and disease-modifying therapeutic solutions for a spectrum of neurodegenerative disorders referred to as tauopathies.  Dysregulation of the Tau protein is the result of some genetic diseases that currently have no effective treatments, and is largely responsible for the onset of Alzheimer’s disease (AD).  By focusing on Tau, we are developing a pipeline of disease-modifying biotherapeutic candidates or products to prevent, delay, or mitigate the underlying dementia or cognitive deficits observed in AD and other related neurodegenerative tauopathies, including:

Frontotemporal dementia (FTD) or Pick’s disease,

Chronic traumatic encephalopathy (CTE) or dementia pugilistica,

Progressive supranuclear palsy (PSP),

Corticobasal degeneration (CBD), and

Familial form of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

Over the past two decades, the pharmaceutical industry has spent billions of dollars (U.S.) trying to develop potential therapies for AD targeting the beta-amyloid (Aβ) protein as the cause of the disorder.  To date, all have failed in late-stage clinical trials and Tau is now viewed as the much more favorable target, especially since Tau pathology correlates much more closely to the progression of dementia and memory impairment observed in AD than Ab.  We at INT are focused on the underlying mechanisms responsible for Tau dysregulation and dementias, and thereby are developing disease-modifying biotherapeutics to prevent, delay, or ameliorate the cognitive decline resulting from tauopathies.  In addition, we intent to target an “orphan or niche” genetic disorder, such as FTD, PSP, or CBD, with our anti-Tau therapeutic candidates to gain prospective “fast-track” designation through the FDA with smaller and more cost effective clinical trials.  Thus, remaining a virtual company will in turn enable INT to significantly reduce overhead and efficiently advance projects into clinical development.